Product Revenue, Net

6 Months Ended

Jun. 30, 2021

Product Revenue, Net

Product Revenue, Net

4.           Product Revenue, Net

ARCALYST

Following the FDA approval of ARCALYST on March 18, 2021, the Company began generating product revenue from sales of ARCALYST in April 2021.

	Six Months Ended
	June 30,
	2021
Product Revenue, net	$	7,704

The following table summarizes balances and activity in each of the product revenue allowance and reserve categories for the six months ended June 30, 2021:

	Contractual		Government
	Adjustments		Rebates		Returns1		Total
Balance at December 31, 2020	$	—	$	—	$	—	$	—
Current provisions relating to sales in the current year		787		288		281		1,356
Adjustments relating to prior years		—		—		—		—
Payments/returns relating to sales in the current year		(242)		—		—		(242)
Payments/returns relating to sales in the prior years		—		—		—		—
Balance at June 30, 2021	$	545	$	288	$	281	$	1,114

(1) Included in the return reserve, is a provision of $236 for a specific return associated with product that was damaged in transit.

Total revenue-related reserves as of June 30, 2021, included in our consolidated balance sheets, are summarized as follows:

	June 30,
	2021
Reduction of accounts receivable		236
Components of accrued expenses		878
Total revenue-related reserves	$	1,114